tiprankstipranks
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
PremiumPress ReleasesCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
2M ago
CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
PremiumPress Releases
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
2M ago
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
PremiumCompany AnnouncementsCorvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
4M ago
Corvus Pharmaceuticals price target lowered to $7 from $8 at Oppenheimer
PremiumThe Fly
Corvus Pharmaceuticals price target lowered to $7 from $8 at Oppenheimer
4M ago
Corvus to initiate Phase 1 trial of soquelitinib for  AD in Q2
PremiumThe Fly
Corvus to initiate Phase 1 trial of soquelitinib for AD in Q2
4M ago
CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsCRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
PremiumPress Releases
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
5M ago
Corvus Pharmaceuticals presents preclinical data for soquelitinib
PremiumThe Fly
Corvus Pharmaceuticals presents preclinical data for soquelitinib
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100